Danielle Bajakian, MD
Vascular Surgery · New York, NYNPI 1659470219
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $91,616 of the $113,437 with a category attached, or 80.8%. 25 manufacturers reported payments, led by Abbott at 54.2% of the total. Reporting peaked in 2024 at $57,954 and has fallen 68.9% since, to $18,039 in 2025. Among vascular surgery clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 194 payments — averaging $584.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$61K
- Boston Scientific$47K
- Cook Medical LLC$1K
- Musculoskeletal Transplant Foundation Inc.$828
- Silk Road Medical, Inc.$826
- AbbVie$302
- plus $2K from 19 others
Across 9 payments — averaging $3715.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$33K
What the payments were for
- Consulting fees$91,61681%
- Speaking & faculty fees$6,7006%
- Grants$2030%
- Travel & lodging$6,9146%
- Food & beverage$8,0047%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 48 | $61,485 |
| Boston Scientific | 46 | $47,033 |
| Cook Medical LLC | 32 | $1,299 |
| Musculoskeletal Transplant Foundation Inc. | 9 | $828 |
| Silk Road Medical, Inc. | 5 | $826 |
| AbbVie(2 entities) | 13 | $302 |
| Medtronic(2 entities) | 4 | $228 |
| Penumbra, Inc. | 1 | $202 |
| Polynovo North America LLC | 2 | $201 |
| Johnson & Johnson | 8 | $189 |
| Philips North America LLC | 3 | $173 |
| Siemens Medical Solutions USA, Inc. | 1 | $128 |
| Integra Lifesciences Corporation | 4 | $104 |
| Terumo Medical Corporation | 2 | $100 |
| Convatec Inc. | 3 | $68 |
| Kerecis Limited | 2 | $67 |
| Tactile Systems Technology Inc | 2 | $36 |
| Smith+Nephew | 2 | $35 |
| Inspiremd Ltd | 1 | $31 |
| Argon Medical Devices, Inc. | 1 | $25 |
| Pfizer | 1 | $23 |
| Lemaitre Vascular, Inc. | 1 | $19 |
| Cardinal Health 200 LLC | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
| Cardiovascular Systems Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ESPRIT$24,378
- SUPERA$14,630
- GENERAL - THERAPIES$11,805
- Omnilink Elite vascular stent system$9,000
- CLINICAL TRIAL PRODUCT$4,020
- OPTICROSS$4,000
- XIENCE V$3,000
- Perclose ProGlide suture mediated closure system$2,700
- OPTIS$2,696
- JETSTREAM SC$2,632
- Supera peripheral stent system$1,631
- ELUVIA$1,219
- ABSOLUTE PRO$1,000
- DRAGONFLY OPSTAR$1,000
- ENROUTE Transcarotid Neuroprotection System$783
- ENHANCE Transcarotid Peripheral Access Kit$783
- ENROUTE Transcarotid Stent$600
- ENROUTE .014 Guidewire$600
- GENERAL VASCULAR INTERVENTION$500
- Zilver PTX$248
How this compares
$113,437 in reported general payments places this provider in the 90th percentile of 405 vascular surgery providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 18 | $16,209 |
| SantylCollagenase Clostridium Hist. | 37 | $13,245 |
| EliquisApixaban | 19 | $11,101 |
| ClopidogrelClopidogrel Bisulfate | 65 | $676 |
| Cilostazol | 36 | $475 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $189 | $16,20918 claims |
| Smith+NephewSantyl | $35 | $13,24537 claims |
| PfizerEliquis | $23 | $11,10119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 405 vascular surgery providers in New York.
Other vascular surgery in New York
- Gary GelbfishNew York$1.9M
- John LantisNew York$922K
- Brian DerubertisNew York$714K
- James McKinseyNew York$616K
- Peter FariesNew York$494K
- Ajit RaoNew York$294K
- Daniel HanNew York$280K
- Todd BerlandNew York$260K
- Thomas MaldonadoNew York$249K
- Karan GargNew York$246K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.